PMID- 33343855
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240330
IS  - 2040-6207 (Print)
IS  - 2040-6215 (Electronic)
IS  - 2040-6207 (Linking)
VI  - 11
DP  - 2020
TI  - Adverse events in second- and third-line treatments for acute and chronic 
      graft-versus-host disease: systematic review.
PG  - 2040620720977039
LID - 10.1177/2040620720977039 [doi]
LID - 2040620720977039
AB  - BACKGROUND: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is 
      associated with an increased risk of graft-versus-host disease (GvHD), a strong 
      prognostic predictor of early mortality within the first 2 years following 
      allo-HSCT. The objective of this study was to describe the harm outcomes reported 
      among patients receiving second- and third-line treatment as part of the 
      management for GvHD via a systematic literature review. METHODS: A total of 34 
      studies met the systematic review inclusion criteria, reporting adverse events 
      (AEs) across 12 different second- and third-line therapies. RESULTS: A total of 
      14 studies reported AEs across nine different therapies used in the treatment of 
      acute GvHD (aGvHD), 17 studies reported AEs of eight different treatments for 
      chronic GvHD (cGvHD) and 3 reported a mixed population. Infections were the AE 
      reported most widely, followed by haematologic events and laboratory 
      abnormalities. Reported infections per patient were lower under extracorporeal 
      photopheresis (ECP) for aGvHD (0.267 infections per patient over 6 months) 
      relative to any of the therapies studied (ranging from 0.853 infections per 
      patient per 6 months under etanercept up to 1.998 infections per patient on 
      inolimomab). CONCLUSION: The reported incidence of infectious AEs in aGvHD and 
      grade 3-5 AEs in cGvHD was lower on ECP compared with pharmaceutical management.
CI  - (c) The Author(s), 2020.
FAU - Velickovic, Vladica M
AU  - Velickovic VM
AD  - Health Economics and Evidence Synthesis Department, Synergus AB, Danderyd, 
      Stockholm, Sweden.
FAU - McIlwaine, Emily
AU  - McIlwaine E
AD  - Health Economics and Evidence Synthesis Department, Synergus AB, Danderyd, 
      Stockholm, Sweden.
FAU - Zhang, Rongrong
AU  - Zhang R
AD  - Health Economics and Evidence Synthesis Department, Synergus AB, Danderyd, 
      Stockholm, Sweden.
FAU - Spelman, Tim
AU  - Spelman T
AUID- ORCID: 0000-0001-9204-3216
AD  - Health Economics and Evidence Synthesis Department, Synergus AB, Kevinge Strand 
      20, Danderyd, Stockholm 182 57, Sweden.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201208
PL  - England
TA  - Ther Adv Hematol
JT  - Therapeutic advances in hematology
JID - 101549589
PMC - PMC7727084
OTO - NOTNLM
OT  - extracorporeal photopheresis
OT  - graft versus host disease
OT  - systematic review
COIS- Conflict of interest statement: VV, EM, RZ, and TS are/were employees of Synergus 
      AB - health economics and market access consulting company, which received a 
      grant from Mallinckrodt Pharmaceuticals to perform the study. Mallinckrodt 
      reviewed the manuscript only to verify accuracy of product mentions.
EDAT- 2020/12/22 06:00
MHDA- 2020/12/22 06:01
PMCR- 2020/12/08
CRDT- 2020/12/21 06:06
PHST- 2020/08/02 00:00 [received]
PHST- 2020/10/29 00:00 [accepted]
PHST- 2020/12/21 06:06 [entrez]
PHST- 2020/12/22 06:00 [pubmed]
PHST- 2020/12/22 06:01 [medline]
PHST- 2020/12/08 00:00 [pmc-release]
AID - 10.1177_2040620720977039 [pii]
AID - 10.1177/2040620720977039 [doi]
PST - epublish
SO  - Ther Adv Hematol. 2020 Dec 8;11:2040620720977039. doi: 10.1177/2040620720977039. 
      eCollection 2020.